Press release
The endocannabinoid system targeted therapeutics market is projected to be over USD 5 billion by 2030, growing at an annualized rate of 30%, claims Roots Analysis
London
Roots Analysis has announced the addition of “Endocannabinoid System Targeted Therapeutics Market, 2020-2030” report to its list of offerings.
Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids.
To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this link - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html or email sales@rootsanalysis.com
Key Market Insights
Over 175 drugs targeting the endocannabinoid system are currently under development
Most cannabinoid-based drug candidates are being developed to target the CB1 and CB2 receptors. Nearly 45% of such drugs are presently being investigated in clinical trials, while 50% are in the preclinical / discovery phase. Majority of these therapies (60%) are designed for oral administration.
More than 60 companies claim to develop endocannabinoid system targeted therapeutics
Post 2010, there has been a significant rise in the number of companies working in this domain; such companies represent 63% of the total number of players. Majority of the firms engaged in this domain (74%) are based in North America, followed by those headquartered in Asia-Pacific (16%), Europe (8%) and Latin America (2%).
Partnership activity has grown at an annualized rate of 35%, between 2017 and 2019
The maximum number of partnerships were observed in 2019 within this segment of the pharmaceutical industry. Majority of these agreements were reported to have been inked for research purposes (20%). In addition, more than 35 merger / acquisition deal were signed between 2016 and 2020; service / facility expansion emerged as the most prominent key value drivers for such agreements.
Close to 600 grants were awarded for supporting research on endocannabinoid system targeted therapeutics, since 2016
Almost 45% of the total amount awarded in the form of grants, was under the R01 (in support of health-related research and development based on the mission of the NIH) mechanism. Further, grants (394) worth USD 147 million were awarded to research projects related to endocannabinoid system.
At present, therapies intended for the treatment of neurological disorders represent the majority share of the overall endocannabinoid system targeted therapeutics market
Most of the therapies targeting neurological disorders are intended for the treatment of epilepsy. In addition to neurological disorders, therapies intended for autoimmune disorders, cancer and genetic disorders are likely to capture significant market opportunity in the foreseen future.
To request a sample copy / brochure of this report, please visit this link - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html or email sales@rootsanalysis.com
Key Questions Answered
Who are the leading industry players in this market?
What are the key clinical conditions addressed by endocannabinoid system targeted therapeutics?
What are the biological receptors targeted by cannabinoid-based therapies?
What are the factors that are likely to influence the evolution of this market?
What are the initiatives undertaken by start-ups and big pharma players engaged in this domain?
What kind of partnership models are commonly adopted by stakeholders in this industry?
How is the current and future market opportunity likely to be distributed across key market segments?
The over USD 5 billion (by 2030) financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across the following segments:
Target Disease Indication
Cancer
Genetic Disorders
Neurological Indications
Others
Route of Administration
Oral
Inhalation
Key Geographies
North America
Europe
Asia-Pacific and the Rest of the World
The report features inputs from eminent industry stakeholders, according to whom, endocannabinoid system targeted therapeutics are considered as a promising alternative for the treatment of a diverse array of symptoms associated with a myriad of human diseases. The report includes detailed transcripts of the discussions held with industry experts.
Oludare Odumosu (Chief Executive Officer, Zelira Therapeutics)
Andrea Small-Howard (Chief Scientific Officer, GB Sciences)
Steeve Néron (Chief Operating Officer, Tetra Bio-Pharma)
Stephen Dahmer (Chief Medical Officer, Vireo Health)
Anthony Kievid (Director of Business Development, Echo Pharmaceuticals)
JANAKAN KRISHNARAJAH (Chief Operating Officer and Chief Medical Officer, iX Biopharma)
The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), drug portfolio, recent developments and an informed future outlook.
GW Pharmaceuticals
Corbus Pharmaceuticals
Tilray
Tetra Bio-Pharma
Botanix Pharmaceuticals
Kalytera Therapeutics
Therapix Biosciences
Echo Pharmaceuticals
Avicanna
GB Sciences
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html or email sales@rootsanalysis.com
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The endocannabinoid system targeted therapeutics market is projected to be over USD 5 billion by 2030, growing at an annualized rate of 30%, claims Roots Analysis here
News-ID: 2232104 • Views: …
More Releases from Roots Analysis
Electronic Health Records Market to Reach $92 Billion by 2035, Growing at 8.3% C …
The global electronic health records market, valued at USD 41 billion in 2025, will reach USD 45 billion in 2026 and is on track to hit USD 92 billion by 2035, compounding at 8.3% annually over the 2026-to-2035 forecast period, according to new research published by Roots Analysis. The growth is being driven by a converging set of forces: surging demand for efficient healthcare data management, government mandates accelerating digital…
Thermoplastic Elastomers Market to Reach $47.25 Billion by 2035 at 5.30% CAGR | …
The global thermoplastic elastomers market, valued at USD 26.77 billion in 2024, will grow to USD 47.25 billion by 2035, advancing at a compound annual growth rate of 5.30% over the forecast period. Demand is accelerating across automotive, medical, and electrical sectors as manufacturers seek materials that combine the flexibility of rubber with the processing advantages of thermoplastics. The convergence of electric vehicle adoption, aging population dynamics, and the shift…
Healthcare Cybersecurity Market to Reach $115 Billion by 2035, Growing at 17.0% …
The global healthcare cybersecurity market, valued at USD 24 billion in 2025, is on course to reach USD 115 billion by 2035, expanding at a compound annual growth rate of 17.0% over the forecast period. Surging ransomware attacks, the rapid digitization of clinical infrastructure, and tightening regulatory mandates are together creating one of the most urgent investment cases in the healthcare technology sector. Organizations that delay action face mounting financial…
In Vitro Diagnostics Market to Reach $190 Billion by 2035, Growing at 4.9% CAGR …
The global in vitro diagnostics market, valued at USD 113 billion in 2025, is projected to reach USD 118 billion in 2026 and climb to USD 190 billion by 2035, advancing at a compound annual growth rate of 4.9% over the forecast period. Rising chronic disease rates, accelerating adoption of point-of-care testing, and growing healthcare expenditure across both developed and emerging economies are converging to make IVD one of the…
More Releases for Chief
The Chief of Staff Association Launches Chief of Staff Academies (TM) - Financia …
The Chief of Staff Association, in collaboration with Deloitte, is launching the Chief of Staff Academies (TM) - Financial Services, a specialised programme designed for chiefs of staff and senior strategic advisors across the sector.
Taking place May 6-8, 2025, at Deloitte in Milan, Italy, this Academy will bring together a select group of chiefs of staff, industry experts, and financial leaders to explore key trends, the future of global finance,…
SigmaBroadband Co., A Georgia Telecommunications Company Appoints New Chief Tech …
Atlanta, Georgia - May 28, 2024 - SigmaBroadband Co. (the "Company" or "SGRB"), an emerging provider of telecommunications solutions, was pleased to announce the appointments of Mr. Glenn Geller as Chief Technology Officer (CTO) and Mr. John Vanover as Chief Financial Officer (CFO).
Mr. Geller brings over 30 years of telecommunications experience to SigmaBroadband Co., most recently from VDOTel following its acquisition by SigmaBroadband Co. With a proven track record of…
Integrative Systems Welcomes New Chief Operating Officer and Chief Finance Offic …
Integrative Systems, a leading provider of innovative technological solutions, proudly announces the addition of two esteemed professionals to its executive team. Effective immediately, Mike Stein joins as Chief Operating Officer (COO), and Jay Amond assumes the role of Chief Finance Officer (CFO).
Mike, an industry veteran with 30+ years of proven expertise in P&L ownership, product development, brand development, and global market development success, brings a wealth of experience in optimizing…
Our Chief Pilot | Philip Goforth
See here: https://rumble.com/vbv521-special-announcement-our-chief-pilot-philip-goforth.html
We are excited to announce that Premier F1 Pilot, Philip Goforth, has Joined Team Möbius as our Chief Pilot!
With more than 15,000 hours of flight under his belt, Phillip is a highly versatile pilot. He has done all types of flying, from Alaskan bush to commercial airline to corporate aviation. He is qualified in a variety of aircraft types and has logged time flying gyrocopters, doing aerobatic performances…
Chief Shisha
Shisha Delivery to homes, events, funcitons small and large.
Chief Shisha is an established company thriving throughout Sydney, delivering & hiring Shisha Statewide. We are built upon foundations of excellence and professionalism, replicating high quality Shisha as well as genuine customer service with every order. With aspirations of continued growth, we are set to meet our customers at their doorsteps as we continue to deliver the most superior quality Shisha to…
T5 Data Centers Names New Chief Operating Officer and New Chief Business Officer
New Senior Executives Named to Oversee T5's Growing Business as Company Leases Space in Six Data Center Campuses Around the Country.
Atlanta, GA, USA (October 8, 2013) -- T5 Data Centers (t5datacenters.com), innovators in providing state-of-the-art, customizable and highly reliable computing support environments for any enterprise, has named two executives to key positions to help oversee customer success as part of the company's growth. Mike Casey will assume a new role…
